Dr Alar Ainla Sweden

The Multifunctional pipette is tool for fast localized solution delivery for bioscientists.

It is comprised of a pneumatic control unit, an interfacing holder and the disposable pipette.

In combination with conventional micromanipulation apparatus, a small 100 micron  virtual flow chamber can be free positioned within a sample.

​Utilizing hydrodynamic confinement, the delivered solution can be localized and rapidly switched without contaminating the sample; enabling large numbers of experiments and parameters to be screened on a single sample dish.

Automation and screening can be achieved through scripting protocols.

Labview and Matlab libraries are now available.

Business Type
Avalance Biotech AB
CTO 

Catharina Althini Sweden

We are a Nordic law firm with a simple business concept : to create value for you. This is the guiding principle in everything we do. This means that we always look for solutions which not only comply with the law, but which also generate commercial advantages. It also means that it's not enough for us to obtain results. We want good results. Irrespective of the industry. Irrespective of which Nordic country is involved. Cross-border.

The business operations conducted within life science companies often involve major risks and opportunities for significant earnings. The risks come not only from the advanced scientific and supervisory environment but also from complicated business models. A key to success is for companies to be able to handle these risks. This demands that the contracts which are produced exhaustively govern all of the risks and that these risks are appropriately allocated between the parties.

NORDIA has a practice group with lawyers experienced in life science to assist national and international companies in the area, both listed companies and private companies.

Business Type
Nordia Law
Jur. kand., associate 

Håkan Arenvid Sweden

Website:
www.vitalis.nu
Business Type
Svenska Mässan/The Swedish Exhibition & Congress Centre

Petter Björquist Sweden

  Cellectis is a biotechnology company that was founded in 1999 upon technology transferred from the Institut Pasteur, one of France’s leading institutions for science and health. The Cellectis stem cells Business Unit combines two Cellectis Group companies dedicated to stem celltechnology. These are Ectycell, based at the Evry Genopole (France), and Cellartis, based in Gothenburg (Sweden), which was acquired by Cellectis in October 2011. To find out more about Cellartis, please visit www.cellartis.com   The goal of the "Cellectis stem cells" Business Unit is to speed up the development of stem cell technology and in particular to find a robust and reproducible way of controlling stem cell production and differentiation, notably through the sharing of knowledge and expertise developed by the two companies, with a view to becoming a major, long-term and stable industrial player in the global marketplace.

Cellartis, a Swedish company founded in 2001, was formed as a spin-off from the University of Gothenburg. From its inception the company has worked on pluripotent stem cells and technologies applied to the search for new drugs, toxicity testing and regenerative medicine. Cellartis has proven expertise in many different areas including:
  • controlling stem cell differentiation into liver and heart cells which offer unrivalled performance in toxicity testing applications;
  • ownership and exploitation of the world's largest stem cell bank (30 proprietary lines);
  • effective industrial rollout of their technologies;
  • alongside leading partners, involvement in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs.

The Cellectis stem cells Business Unit has ambitious objectives.
  • To industrialize pluripotent stem cells;
  • To develop industrial in vitro tools predictive of human physiology and genetic diversity, such as tools for the drug and cosmetic industries, as well as for research, and that can be immediately used in industrial molecular screening and selection processes;
  • To develop major partnerships, particularly in the field of regenerative medicine;
  • To take a strategic industrial role in order to set standards in an emerging market, forge a strong pioneering position in the areas of focus, and build a genuine industrial sector based around stem cells and a competitive industrial cluster.
Business Type
Cellectis
LinkedIn logo VP Regenerative Medicine, Senior Principal Scientist 

Magnus Bjorsne Sweden

Business Type
AstraZeneca
LinkedIn logo Business Development Director & VC Liaison at AstraZeneca 

Ulf Boberg Sweden

 

NovaHep was founded in 2005 on the basis of research conducted at the Huddinge unit of the Karolinska Institute in Stockholm. The company is now based in Gothenburg, Sweden, at the Biotech Center.
NovaHep is active within the field of regenerative medicine, developing stem cell technology with a wide range of applications.
The main area of focus is the production of biological, individualised vessels, in collaboration with the University of Gothenburg. The vessels can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The product is unique and patented. Through an improved alternative to traditional treatments, NovaHep will deliver a life changing impact to patients and provide for major benefits for hospitals, healthcare providers and society – globally.
NovaHep also works with liver stem cells for the purpose of developing a system in which drugs can be tested without the use of laboratory animals.

 
Business Type
NovaHep AB
LinkedIn logo Consultant 

Mr Karl Branzen Sweden

Life Science Foresight Institute is a research institute formed to assist companies and organisations in the Life Science sector with business intelligence and futures studies.

The institute will provide client organisations with knowledge to facilitate their strategic decision-making – enabling them from the very start to hit the mark on everything from major investments in healthcare infrastructure to product development within a small enterprise.

Business Type
Life Science Foresight Institute
Senior Analyst 

Dr Lars-Erik Briggner Sweden

Experts in all areas related to solid state characterization of pharmaceutical material. Unique knowledge related to development of Dry Powder Inhalation products, but cover also oral product development area.

Business Type
Dr Lars-Erik Briggner
Adroit Science AB
Project Manager 

Adam Bruce Sweden

TikoMed is a specialty biopharmaceutical company founded in a cradle of fierce entrepreneurship, cutting edge science and industrial competence. 

"TikoMed is developing and commercializing life-saving products for severe diseases" 

We apply advances in innate immunology to identify mechanisms and develop new products.

Our mission is to develop and commercialize innovative treatments for severe and life-threatening diseases, for the benefit of patients, who lack satisfactory treatment options.

Website:
www.tikomed.com
Business Type
Adam Bruce
TikoMed
LinkedIn logo Founder, Boardmember and Business Development 

Mr Göran Conradson Sweden

Venaticus is a provider of international high level, independent advice and hands-on senior management to firms in the Life Science sector. 
Venaticus provides expert advice and hands-on senior management on commercialisation of technology bases such as; inventions, platform technologies and out-/in-licensing of product rights.
Typical clients are small biotech- and start-up companies that are in the phase of generating cash flow, and profit from their technology base.

Business Type
Venaticus AB